Chief Executive Officer
Mr. Fowler joined Liquidia in 2008 after seven years in an executive leadership role at Johnson & Johnson (J&J). While at J&J, he served as President of Centocor, Inc., a multi-billion-dollar subsidiary focused on the development and commercialization of industry-leading biomedicines used to treat chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for commercial product launches and continued the company’s legacy of double-digit growth for its flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler served as President of Ortho-McNeil Neurologics Inc. and Vice President of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. He also had a 13-year career at Eli Lilly and Company where he held a variety of sales, marketing and business development roles with increasing responsibilities in the pharmaceutical and medical device divisions. Mr. Fowler received a B.S. in Pharmacy and an MBA from the University of North Carolina at Chapel Hill.
Chief Operations Officer
Mr. Lippe is responsible for all aspects of operations at Liquidia, including manufacturing, supply chain management, quality, facilities, and program management. Prior to joining Liquidia in 2015, Mr. Lippe served as an Executive Vice President of Operations and Chief Operations Officer at Alexza Pharmaceuticals. In these roles, he had operational oversight for the scale-up and optimization of supply that supported the launch of the company’s first commercial product, and he advanced a platform proof-of-concept which accelerated the company’s product pipeline. He also worked as the Head of Global Operations & Operational Excellence at Ironwood Pharmaceuticals, Inc., and as the Head of Manufacturing for one of Genentech’s Vacaville operating facilities. Mr. Lippe spent 10 years at Lawrence Livermore National Laboratory and six years as an officer in the U.S. Coast Guard. He received his MPH and MBA degrees from the University of California, Berkeley, and received a B.S. degree in Marine Engineering from the United States Coast Guard Academy.
Interim Chief Financial Officer
Mr. Bariahtaris joined Liquidia in August 2020 with 34 years of experience in corporate finance and management. Prior to Liquidia, he spent nearly 24 years at Johnson & Johnson (J&J) serving in several executive roles with increasing responsibility. Most recently, Mr. Bariahtaris served as J&J’s Worldwide Vice President, Corporate Internal Audit, where he acted as the Chief Audit Executive for the $80 billion healthcare company. Mr. Bariahtaris served in several additional J&J leadership roles including CFO & Vice President of Finance for Janssen Americas where he provided financial leadership for the $20+ billion pharmaceuticals business and Vice President, Worldwide Finance and CFO for Ortho Clinical Diagnostics where he provided financial leadership for the $2 billion fully integrated global diagnostics business. Mr. Bariahtaris began his career with Proctor and Gamble (P&G) working initially in supply chain management roles before his transition to Corporate Finance. He received a Bachelor of Science (B.S) from Cornell University and a Master of Business Administration (MBA) from The Wharton School at the University of Pennsylvania.
Chief Medical Officer
Dr. Shah joined Liquidia in May 2020 and oversees all aspects of research, clinical development, medical affairs, and regulatory affairs for the company. Prior to Liquidia, Dr. Shah served as Head of Global Specialty Clinical Development at Teva Pharmaceuticals with oversight of all phases of clinical development across all therapeutic areas including CNS, immunology, respiratory, oncology and biosimilars. Prior to Teva, Dr. Shah served as Senior Vice President, Scientific and Clinical Development at Altana Pharma US, where he built and led their clinical development function, including clinical research and operations, medical affairs, regulatory affairs and quality assurance, pharmacovigilance and drug safety, biostatistics and data management. He began his career at GlaxoSmithKline (GSK), where he held roles of increasing responsibility and most recently served as U.S. Head, Respiratory and Inflammation, Discovery Medicine and Clinical Pharmacology responsible for early-stage clinical development of new therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and rhinitis. Dr. Shah received a M.D. degree from the Hershey Medical College at Pennsylvania State University. He completed his residency in Internal Medicine at the University of North Carolina and fellowship in Allergy, Asthma and Clinical Immunology at Johns Hopkins University.
Senior Vice President, Commercial
Ms. Thomas is responsible for the development and leadership of Liquidia’s commercial strategy. Prior to joining Liquidia, Ms. Thomas was Senior Vice President, Strategic Group Planning at Harrison and Star, a global healthcare marketing agency. Prior to that, she served as Senior Vice President of the Surgical & Perioperative Care Business Unit at The Medicines Company where she led the global commercialization of IONSYS®, the first drug-device combination product for acute postoperative pain. Prior to The Medicines Company, Ms. Thomas was at Janssen Pharmaceuticals (a Johnson & Johnson company) where she held various senior leadership positions including Vice President, Market Strategy & Access for Latin America, Vice President, New Business and New Product Planning, and Director of Marketing, Analgesic Franchise. She has also held management positions at Bristol-Myers Squibb and Hoffman-La Roche Pharmaceuticals. Ms. Thomas obtained her Master of Business Administration in a dual program from the McDonough School of Business at Georgetown University and ESADE Business School in Barcelona, Spain. She received a Bachelor of Science in Health Planning and Administration from Penn State University.
Vice President, Corporate Development & Strategy
As Vice President, Corporate Development & Strategy at Liquidia, Mr. Adair is responsible for pursuing collaboration and licensing opportunities for the company. Prior to joining Liquidia in 2016, Mr. Adair led business development efforts at BioCryst Pharmaceuticals as their Executive Director of Corporate Development. His work included the commercial launch and subsequent partnering of the company’s first FDA approved drug. He also worked at MedImmune/AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Mr. Adair worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He received an MBA from the Tuck School of Business at Dartmouth College and a B.S. in Chemistry from Wake Forest University.
Senior Vice President, Human Resources
As Senior Vice President, Human Resources, Ms. Gordon-Krawchick is focused on building a team-based culture of innovation and excellence at Liquidia. In addition to leading the company’s workforce strategies and operations, she oversees recruiting and onboarding, training and leadership development, compensation planning and total rewards, and organizational development. Prior to joining Liquidia in 2010, Ms. Gordon-Krawchick held multiple Human Resources Business Partner roles at Johnson & Johnson (J&J) across research & development, sales, marketing, commercial and operations. She also led early talent recruitment and development for J&J’s commercial groups across the pharmaceutical businesses. Ms. Gordon-Krawchick received a business degree from George Washington University.
Our values stem from our core principals. They reflect what we care about at Liquidia and how we recognize the tremendous efforts of our team members.